FNCH Stock Price, Fh Therapeutics Group, Inc. Quote, Chart

Market Summary

USD2.24-0.12

Market Closed

-5.08%

FNCH Stock Price

View Fullscreen

FNCH RSI Chart

FNCH Valuation

Market Cap

3.6M

Price/Earnings (Trailing)

-0.05

Price/Sales (Trailing)

33.62

EV/EBITDA

0.28

Price/Free Cashflow

-0.11

FNCH Price/Sales (Trailing)

FNCH Profitability

EBT Margin

-5032.55%

Return on Equity

-326.84%

Return on Assets

-135.08%

Free Cashflow Yield

-875.89%

FNCH Fundamentals

FNCH Revenue

Revenue (TTM)

1.6M

Rev. Growth (Yr)

184.06%

Rev. Growth (Qtr)

-6.67%

FNCH Earnings

Earnings (TTM)

-74.8M

Earnings Growth (Yr)

88.74%

Earnings Growth (Qtr)

-25.87%

Breaking Down FNCH Revenue

Last 7 days

10.3%

Last 30 days

-18.2%

Last 90 days

-21.4%

Trailing 12 Months

-81.3%

How does FNCH drawdown profile look like?

FNCH Financial Health

Current Ratio

6.33

FNCH Investor Care

Shares Dilution (1Y)

0.06%

Diluted EPS (TTM)

-47.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	932.0K	991.0K	1.2M	107.0K
2022	14.1M	9.7M	5.3M	861.0K
2021	9.5M	10.0M	19.5M	18.5M
2020	0	0	0	7.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Finch Therapeutics Group, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	smisek jeffery a	sold	-17,069	2.57	-6,642	-
Mar 28, 2024	smisek jeffery a	sold	-4,176	2.61	-1,600	-
Nov 22, 2023	smisek jeffery a	sold	-5,350	3.64	-1,470	-
Jun 09, 2023	graf susan e	bought	1,352	0.27	5,010	-
Feb 21, 2023	blaustein marc	sold	-1,755	0.38	-4,619	chief operating officer
Oct 21, 2022	blaustein marc	sold	-5,054	1.39	-3,636	chief operating officer
Oct 21, 2022	vittiglio joseph	sold	-5,054	1.39	-3,636	chief business & legal officer
Jun 13, 2022	vittiglio joseph	acquired	-	-	35,000	chief business & legal officer
Jun 13, 2022	blaustein marc	acquired	-	-	35,000	chief operating officer
Dec 20, 2021	haft nicholas	bought	649,993	10.18	63,850	-

Which funds bought or sold FNCH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	Moisand Fitzgerald Tamayo, LLC	sold off	-100	-11.00	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	7.86	-46,226	139,938	-%
Feb 14, 2024	MSD Partners, L.P.	sold off	-100	-26,485	-	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	new	-	43.00	43.00	-%
Feb 14, 2024	Ikarian Capital, LLC	unchanged	-	-10,268	24,881	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	unchanged	-	-87,952	213,091	-%
Feb 14, 2024	Ancora Advisors, LLC	sold off	-100	-2,761	-	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 13, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	509	509	-%
Feb 13, 2024	MORGAN STANLEY	unchanged	-	-193	444	-%

Are Funds Buying or Selling FNCH?

Are funds buying FNCH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FNCH

No. of Funds

Unveiling Finch Therapeutics Group, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Dec 13, 2023	ugwumba chidozie	9.99%	160,366	SC 13G
Feb 14, 2022	walton thomas layton	0%	0	SC 13G
Feb 14, 2022	ugwumba chidozie	7.37%	3,500,000	SC 13G

Recent SEC filings of Finch Therapeutics Group, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 03, 2024	8-K	Current Report
Mar 29, 2024	4	Insider Trading
Mar 28, 2024	144	Notice of Insider Sale Intent
Mar 25, 2024	10-K	Annual Report
Feb 23, 2024	8-K	Current Report

Peers (Alternatives to Finch Therapeutics Group, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.46	11.9	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.19	3.81	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.33	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Finch Therapeutics Group, Inc. News

Latest updates

Finch Therapeutics Group, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-100.0%	-	392,000	420,000	425,000	8,000	138,000	361,000	583,500	806,000	11,343,000	2,830,000	3,553,000	1,807,000	1,771,000	2,349,000	1,792,000
Operating Expenses	-4.3%	3,620,000	3,781,000	9,881,000	67,482,000	27,760,000	40,770,000	22,990,000	24,934,000	19,868,000	21,276,000	19,846,000	17,527,000	14,939,000	11,852,000	10,709,000	9,655,000
S&GA Expenses	25.3%	4,681,000	3,735,000	8,877,000	9,617,000	9,040,000	9,584,000	8,164,000	9,404,000	5,065,000	5,739,000	5,882,000	4,552,000	6,372,000	2,807,000	2,574,000	2,258,000
R&D Expenses	-Infinity%	-796,000	-	203,000	8,588,000	11,551,000	11,859,000	13,923,000	15,530,000	14,803,000	15,537,000	13,964,000	12,975,000	8,567,000	9,045,000	8,135,000	7,397,000
EBITDA Margin	39.1%	-49.36	-81.04	-137	-162	-125	-19.23	-7.44	-4.64	-3.01	-2.58	-5.11	-4.68	-4.99	-	-	-
Interest Expenses	-	-	-	-	202,000	334,000	334,000	71,000	2,000	2,000	2,000	2,000	3,000	3,000	4,000	3,000	1,000
Income Taxes	-	-	-	-	-3,461,000	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	7.1%	-2,245,000	-2,416,000	-6,950,000	-67,400,000	-27,008,000	-40,371,000	-22,700,000	-24,567,000	-19,055,000	-9,955,000	-15,169,000	-13,981,000	-13,091,000	-10,090,000	-8,259,000	-7,901,000
EBT Margin	39.6%	-50.33	-83.35	-143	-168	-133	-20.21	-7.87	-4.87	-3.14	-2.67	-5.25	-4.79	-5.10	-	-	-
Net Income	-25.9%	-3,041,000	-2,416,000	-6,950,000	-62,347,000	-27,008,000	-40,371,000	-22,700,000	-24,567,000	-19,055,000	-9,955,000	-15,169,000	-13,981,000	-13,091,000	-10,090,000	-8,259,000	-7,901,000
Net Income Margin	39.9%	-47.64	-79.29	-137	-163	-133	-20.21	-7.87	-4.87	-3.14	-2.67	-5.25	-4.79	-5.10	-	-	-
Free Cashflow	29.8%	-3,692,000	-5,261,000	-9,157,000	-13,395,000	-14,323,000	-19,422,000	-16,733,000	-26,555,000	-15,789,000	-16,713,000	-26,566,000	-24,048,000	-10,499,000	-7,131,000	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-6.9%	55.00	59.00	67.00	79.00	163	188	228	205	225	233	250	266	165
Current Assets	-13.6%	26.00	30.00	36.00	43.00	75.00	91.00	111	123	143	156	177	198	106
Cash Equivalents	-12.7%	25.00	29.00	34.00	42.00	71.00	85.00	105	107	133	149	168	193	100
Net PPE	-6.8%	1.00	1.00	1.00	1.00	16.00	17.00	18.00	19.00	20.00	20.00	18.00	16.00	7.00
Goodwill	-	-	-	-	-	-	-	18.00	18.00	18.00	18.00	18.00	18.00	18.00
Liabilities	-3.5%	32.00	34.00	39.00	46.00	67.00	67.00	69.00	25.00	23.00	13.00	22.00	26.00	28.00
Current Liabilities	-16.3%	4.00	5.00	10.00	13.00	15.00	14.00	15.00	17.00	15.00	9.00	10.00	12.00	11.00
Long Term Debt	-	-	-	-	-	15.00	15.00	15.00	-	-	-	-	2.00	2.00
LT Debt, Non Current	-	-	-	-	-	15.00	15.00	15.00	-	-	-	-	2.00	2.00
Shareholder's Equity	-11.3%	23.00	26.00	28.00	35.00	96.00	121	159	180	202	220	228	239	-
Retained Earnings	-0.9%	-350	-347	-344	-339	-275	-248	-208	-185	-160	-141	-131	-116	-102
Additional Paid-In Capital	0.0%	373	373	373	372	371	369	367	365	363	362	360	356	7.00
Shares Outstanding	0.0%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	2.00	0.00	0.00
Float	-	-	-	9.00	-	-	-	76.00	-	-	-	355	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	29.6%	-3,706	-5,261	-9,157	-13,381	-14,272	-19,094	-15,839	-25,646	-13,787	-14,349	-23,783	-15,214	-10,282	-6,914	-8,162	-5,971
Share Based Compensation	-66.0%	114	335	300	1,180	1,793	2,101	1,830	2,120	1,406	1,515	905	335	2,876	57.00	88.00	78.00
Cashflow From Investing	155.0%	51.00	20.00	1,270	-14.00	-51.00	-328	-894	-909	-2,002	-2,364	-2,731	-8,824	-2,146	-217	-198	-72.00
Cashflow From Financing	-	-	-	4.00	-16,159	52.00	41.00	14,775	5.00	70.00	45.00	1,628	117,367	-229	89,905	1,803	-4.00

FNCH Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
REVENUE:
Total revenue	$ 107	$ 861
OPERATING EXPENSES:
Research and development	7,199	52,863
General and administrative	26,910	36,192
Impairment of goodwill	0	18,057
Impairment of in-process research and development	32,900	0
Impairment of long-lived assets	13,141	6,926
Restructuring	3,818	2,416
Total operating expenses	83,968	116,454
Net loss from operations	(83,861)	(115,593)
OTHER INCOME, NET:
Interest income, net	1,570	252
Gain on lease termination	752	0
Loss on loan extinguishment	(1,366)	0
Gain (loss) on sale and disposal of fixed assets, net	637	(7)
Sublease and other income	4,053	702
Total other income, net	5,646	947
Loss before income taxes	(78,215)	(114,646)
Income tax benefit	3,461	0
Net loss	$ (74,754)	$ (114,646)
Net loss per share attributable to common stockholders, basic	$ (46.59)	$ (72.12)
Net loss per share attributable to common stockholders, diluted	$ (46.59)	$ (72.12)
Weighted-average common stock outstanding, basic	1,604,549	1,589,584
Weighted-average common stock outstanding, diluted	1,604,549	1,589,584

FNCH Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 25,124	$ 71,038
Accounts receivable	0	144
Prepaid expenses and other current assets	723	3,369
Total current assets	25,847	74,551
Property and equipment, net	594	15,936
Operating right-of-use assets	26,584	32,752
In-process research and development	0	32,900
Restricted cash, non-current	2,348	2,767
Other assets	0	4,033
TOTAL ASSETS	55,373	162,939
CURRENT LIABILITIES:
Accounts payable	141	1,097
Accrued expenses and other current liabilities	2,220	10,161
Operating lease liabilities, current	1,723	3,431
Total current liabilities	4,084	14,689
Deferred tax liability	0	3,461
Loan payable, non-current	0	14,653
Operating lease liabilities, non-current	28,403	34,255
Other liabilities	0	170
Total liabilities	32,487	67,228
COMMITMENTS AND CONTINGENCIES (Note 10)
Preferred stock (undesignated), $0.001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2023 and 2022	0	0
STOCKHOLDERS' EQUITY:
Common stock, $0.001 par value; 200,000,000 shares authorized as of December 31, 2023 and 2022;1,605,763 and 1,601,717* shares issued and outstanding as of December 31, 2023 and 2022, respectively	2	2
Additional paid-in capital	373,279	371,350
Accumulated deficit	(350,395)	(275,641)
Total stockholders' equity	22,886	95,711
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 55,373	$ 162,939

About Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

WEBSITE	finchtherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	18

Finch Therapeutics Group, Inc. Frequently Asked Questions

What is the ticker symbol for Finch Therapeutics Group, Inc.? What does FNCH stand for in stocks?

FNCH is the stock ticker symbol of Finch Therapeutics Group, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Finch Therapeutics Group, Inc. (FNCH)?

As of Fri Apr 19 2024, market cap of Finch Therapeutics Group, Inc. is 3.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FNCH stock?

You can check FNCH's fair value in chart for subscribers.

What is the fair value of FNCH stock?

You can check FNCH's fair value in chart for subscribers. The fair value of Finch Therapeutics Group, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Finch Therapeutics Group, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FNCH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Finch Therapeutics Group, Inc. a good stock to buy?

The fair value guage provides a quick view whether FNCH is over valued or under valued. Whether Finch Therapeutics Group, Inc. is cheap or expensive depends on the assumptions which impact Finch Therapeutics Group, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FNCH.

What is Finch Therapeutics Group, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, FNCH's PE ratio (Price to Earnings) is -0.05 and Price to Sales (PS) ratio is 33.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FNCH PE ratio will change depending on the future growth rate expectations of investors.